Back
Speaker illustration

undefined undefined undefined

Presentations

PCSK-9 inhibitors vs. ezetimibe for secondary prevention: utilization disparities and clinical outcomes

Event: ESC Congress 2025

Topic: Pharmacotherapy

Session: Pharmacotherapy to improve outcomes in coronary disease

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources